PropertyValue
?:abstract
  • Objectives: To evaluate the efficacy of TruScreen (TS01) for high-risk human papillomavirus (HR-HPV) women compared with other methods in reducing colposcopy referral rates in hospitals. Methods: A single-center, prospective, case-control study was conducted from December 2019 to June 2020. Results: Among 139 (46.2%) HR-HPV positive patients, 58 were CIN1, 52 were CIN2-3 and 29 had cervical cancer (n = 29). The sensitivity and specificity of detecting CIN2+ by TS01, colposcopy and HPV16/18 testing were 96.3% and 46.4%, 85.2% and 40.5% and 59.3% and 74.1%, respectively. The highest sensitivity was 96.3% at HPV16/18 and TS01 (each positive results), and the highest specificity was 83.6% at HPV16/18 and TS01 (both positive) for CIN2+ compared with the other methods. Conclusion: TS01 is a noninvasive screening method and can be used to diagnose cervical lesions quickly. It is especially suitable as triage tool for HR-HPV-positive women facing SARS-Cov-2 exposure and infection risks in hospital.
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.2217/fon-2020-0928
?:journal
  • Future_oncology
?:license
  • cc-by-nc-nd
?:pmid
?:pmid
  • 33331168
?:publication_isRelatedTo_Disease
?:source
  • Medline
?:title
  • TruScreen detection of cervical tissues for high-risk human papillomavirus-infected women during the coronavirus disease 2019 pandemic.
?:type
?:year
  • 2020-12-17

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/6mmucetl>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/6mmucetl>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all